Eimeryl

Quick links to important sections

Eimeryl

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eimeryl

Property Description
Active ingredient Amprolium
Form Soluble powder, Oral solution, Feed premix
Pharmacological class Coccidiostat, Antiprotozoal drug
General purpose Control of protozoal infections
Origin Synthetic compound

What Type of Medicine is Eimeryl? (Defining the Identity and Class)

Eimeryl is a specific synthetic compound used in veterinary medicine, formally classified as a coccidiostat due to its targeted action against protozoal parasites. The drug's active ingredient is Amprolium, a Pyridinium derivative that represents a single-ingredient solution. As an anticoccidial agent, its role is to control parasites that cause disease, such as Eimeria species. Amprolium's identity as an antiprotozoal drug is recognized for its selective inhibition profile, supporting its general use in managing these protozoal burdens.


Composition and Available Forms of Amprolium (Focus on Presentation)

The preparation, Eimeryl, is designed for oral administration through several distinct dosage form(s), primarily including a soluble powder, an oral solution, and a feed premix. The core active component is always Amprolium, often present as the hydrochloride salt (Amprolium HCl). The availability of Eimeryl as a soluble powder and a feed premix allows for large-scale administration via water or feed. These formulations, whether blended with inert carriers or suspended in an aqueous vehicle, are tailored to facilitate the systemic delivery of the agent.


The Purpose: How Eimeryl Acts as a Competitive Antagonist

Eimeryl functions based on an antimetabolite effect, specifically acting as a competitive antagonist against a vital nutrient required by the target parasite. The agent works through competitive inhibition of Thiamine uptake by the coccidia. This mechanism means the drug directly blocks the parasite's ability to absorb the essential B-vitamin, Thiamine (Vitamin B1), which it needs for metabolism. This nutrient mimicry prevents the parasite from utilizing the necessary resources, thereby restricting the organism's ability to grow and replicate and establishing the drug's fundamental benefit in controlling the parasite population.

What side effects are possible with Eimeryl?

Possible Side Effects and Safety Information (Esmolol Hydrochloride)

Official regulatory documents classify the medicine's adverse reactions and safety profile based on frequency and system affected. Reactions documented as Very Common (ge1/10) include hypotension (low blood pressure) and excessive diaphoresis (sweating). Effects classified as Common (ge1/100 to <1/10) involve injection site reactions, nausea, vomiting, dizziness, and fatigue. These adverse reactions are grouped by the systems they affect, primarily involving Vascular Disorders and Cardiac Disorders.

Serious Adverse Reactions officially documented in labeling include severe events such as Asystole (cardiac arrest), Severe Sinus Bradycardia, and Decompensated Heart Failure. The risk of Skin Necrosis is noted as a potential complication arising from leakage at the infusion site.

Due to the medicine's rapid elimination, its safety profile includes a time-related pattern: pharmacological side effects are expected to resolve quickly, typically within 30 minutes of discontinuation.

The label strictly outlines conditions for use. The medicine is contraindicated in patients with pre-existing conditions such as severe sinus bradycardia, heart block greater than first degree, and cardiogenic shock. Furthermore, safety and effectiveness have not been established for use in the pediatric or older adult populations, and caution is noted for patients with renal impairment due to potential Hyperkalemia risk.

Overdose and Emergency Response

The official regulatory profile for Eimeryl (Esmolol) overdose documents manifestations of profound hemodynamic depression. Key signs include severe hypotension (dangerously low blood pressure) and severe bradycardia (abnormally slow heart rate). Patients may also experience CNS effects such as dizziness, extreme fatigue, drowsiness, unconsciousness, and irregular breathing. The labeling states that overdose can progress to life-threatening events, including cardiac arrest and ultimately, death. The most severe outcomes are marked by a complete absence of measurable blood pressure or pulse.

The regulatory standard for emergency response is clear: in the event of any suspected overdose symptoms, the infusion should be discontinued immediately. Patients must get emergency help immediately. Management relies on symptomatic and supportive treatment, as no specific antidote is known. A population-specific consideration noted in the labeling is that the excretion of the active acid metabolite is significantly decreased in patients with renal disease, potentially prolonging effects and necessitating close monitoring of the patient's cardiovascular status.

Therapeutic Uses of Eimeryl

What Eimeryl treats: main uses and benefits

Eimeryl, which contains the active substance esmolol hydrochloride, is a compound applied across domains where additional symptomatic support is needed in a hospital setting. Esmolol is indicated for the short-term treatment of symptoms related to heightened physiological activity. Specifically, this medicine is used to manage supraventricular tachycardia, including conditions like atrial fibrillation and atrial flutter.

This therapeutic domain is relevant when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations of heart rhythm disturbances. Eimeryl may assist with the short-term treatment of tachycardia and hypertension that occur during surgery (perioperative and postoperative phases), offering symptomatic relief when symptoms become temporarily overwhelming. It provides support that helps ease the overall symptom burden and assists with maintaining functional stability during these critical, acute episodes.

Quick Fact: Relief for symptoms related to heightened physiological activity.


This medication supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Eimeryl — Official Regulatory Information

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults in short-term, emergent circumstances only.
Populations for whom use is contraindicated Patients with severe sinus bradycardia, second or third-degree heart block, cardiogenic shock, or decompensated heart failure.
Age-related eligibility rules Safety and efficacy have not been established in pediatric patients (< 18 years). Older adults require caution due to potential age-related kidney issues.
Condition-specific eligibility rules Use with caution in patients with severe renal impairment due to the risk of metabolite accumulation. Caution is also advised in patients with reactive airways disease or diabetes mellitus.
Pregnancy and lactation eligibility Not recommended during pregnancy or breastfeeding. Use during pregnancy is permitted only if the potential benefit outweighs the risk (FDA Category C).

Eligibility classifications (high-level)

Classification Example Population
Contraindicated (Absolute exclusion) Decompensated heart failure, second-degree AV block, severe hypotension.
Not Recommended (Strong caution) Pediatric patients, pregnant or breastfeeding individuals.
Use with Caution (Risk assessment required) Patients with severe renal impairment or reactive airways disease.

Resulting eligibility structure

Official eligibility statements:

  • Use is restricted exclusively to the adult population.
  • The medicine is strictly contraindicated in patients with pre-existing, severe cardiac rhythm or function issues, including severe bradycardia and cardiogenic shock.
  • Safety and efficacy have not been established for children and adolescents under 18 years of age.
  • Use is not recommended for women who are pregnant or breastfeeding.

Connection to the overall eligibility profile: Governmental regulatory documents clearly define who can and cannot use Eimeryl by establishing stringent exclusion criteria centered on the patient’s existing cardiac, conduction, and organ function. The regulatory profile confines the drug to the adult population in acute, short-term settings, formally prohibiting its use in individuals with specific, severe cardiovascular compromises.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Official regulatory documentation identifies specific substance categories and compounds that interact with Eimeryl (Amprolium), primarily impacting its efficacy and safety when compounded in feed. These interactions are classified as a combination of official prohibition of co-use and pharmacodynamic efficacy compromise.

Documented Interaction Profile

The interaction profile is defined by constraints on feed composition and functional antagonism against nutritional supplements. Co-administration with certain substances is either prohibited or results in a loss of the product's intended therapeutic effect.

Interaction Type Interacting Substance / Category Official Restriction or Effect
Prohibited Co-use Bentonite (Feed Additive) Use is explicitly prohibited when preparing medicated feed mixtures, as stated in regulatory labeling.
Efficacy Compromise Thiamine (Vitamin B1) and B-Complex Vitamins Concurrent administration may reduce the product's effectiveness due to functional antagonism, where Amprolium interferes competitively with the uptake of Thiamine.
Product Incompatibility Choline (High-Level Concentrates) Some regulatory monographs restrict mixing the product with concentrates containing high levels of choline due to potential material incompatibility issues.

The official regulatory structure for Eimeryl is defined by a mandated prohibition on co-administration with specific materials like bentonite, and a functional antagonism against supplementary B Vitamins. These constraints govern the official restrictions on combining the product with other substances and confirm that the interaction profile focuses on efficacy and material compatibility.

Mechanism of Action

Eimeryl's active component, Amprolium, functions as a structural analog and antimetabolite. Its mechanism of action targets the parasite's vital nutrient supply by exploiting a difference in affinity between the parasite and host transport systems for the same nutrient.

Competitive Blockade of Thiamine Uptake

Amprolium exerts a competitive antagonist effect by binding to the parasite's specific Thiamine ( Vitamin B1) transport system on its cell membrane. This selective blockade physically prevents the parasite from absorbing the essential vitamin, initiating a targeted state of cellular deficiency.

Metabolic Shutdown and Lifecycle Arrest

The resulting internal Thiamine deficiency rapidly disrupts the parasite's core carbohydrate metabolism by preventing the synthesis of vital co-factors. This lack of essential metabolic fuel directly impairs the highly energy-dependent, rapid asexual multiplication stage (Schizogony) of the Eimeria parasite. The physiological consequence of this lifecycle arrest is the prevention of further proliferation, controlling parasitic multiplication, which reduces the associated intestinal pathology.

Mechanism Limitations

The mechanistic action can be functionally reduced if high external concentrations of Thiamine overwhelm the competitive block. Furthermore, the Eimeria parasite can develop resistance through genetic changes that reduce the target transporter's affinity for the drug, thereby altering the functional mechanism.

Dosage and Administration Information

How to use Eimeryl

Eimeryl (esmolol hydrochloride) is administered exclusively through the intravenous (IV) route and is not formulated for oral use. The administration protocol involves two distinct phases: a rapid initial injection followed by a continuous, adjustable infusion.

Usage typically begins with a calculated loading dose of 500 mcg/kg, which is administered as an IV bolus over approximately 1 minute. This rapid injection is immediately followed by the initiation of a maintenance infusion to sustain the compound's effect. The dosage range for the maintenance infusion is 50 to 200 mcg/kg per minute. The maximum recommended rate for maintenance infusions is 200 mcg/kg/min, though specialized use in perioperative hypertension may permit rates up to 300 mcg/kg/min.

The continuous infusion rate must be carefully titrated according to the patient's individual response. The infusion rate should be adjusted incrementally, typically in 50 mcg/kg/min steps, and no more frequently than every 4 minutes. Due to its rapid-onset properties, the drug is designated for short-term treatment only and is used in a closely monitored, acute care setting. Administration may be continued for up to 48 hours, and established procedures are followed for gradually reducing the infusion rate when transitioning to an oral alternative. Concentrated forms of the solution must be diluted to the appropriate concentration prior to use; however, no routine dose adjustment is specified for individuals with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eimeryl (Esmolol)

This section summarizes the key types of research conducted on Eimeryl, which contains the active ingredient esmolol, focusing only on the structure of the evidence and what studies have examined for Eimeryl's authorized uses.


Evidence for Rate Control in Acute Tachycardia Conditions

The research base for rapid heart rate conditions, such as atrial fibrillation and atrial flutter, primarily relies on short-term, randomized controlled trials (RCTs) and scientific reviews. These studies research explored the rapid change in physiological variables during periods of increased symptom activity. Researchers primarily focused on acute outcomes describing episodic or acute changes, specifically monitoring how quickly the heart rate was measured to change and the maintenance of that measurement within a targeted range.

Findings describe patterns observed in these studies regarding the immediate measured physiological response in the adult populations studied. Due to its design for short-term administration, the available evidence contributes mainly to understanding short-term physiological response patterns over intervals typically lasting up to two days (48 hours).


Research on Hemodynamic Control During Surgery

Research examined temporary physiological imbalance, specifically rapid heart rate and high blood pressure, occurring around the time of surgery, during anesthesia, or in the immediate recovery phase. The research here also consists of RCTs and comparative studies applied in studies examining temporary physiological imbalance. Findings describe patterns observed in the studies related to the rapid onset and offset of the measured physiological variables.

Subgroup findings are uncertain for specific, high-risk patient groups not widely represented in the primary research. There is limited information for long-term outcomes or functional recovery extending beyond the acute postoperative window where the medicine is used.


The State of Long-Term Evidence and Follow-up

Long-term effects are not fully established and long-term outcomes are not well characterized. Research provides context about group patterns but not individual predictions about patient health measures weeks or months after the acute treatment concludes. The majority of the evidence comes from studies on adult populations requiring acute evaluation of acute physiological variables in hospital settings. Data for certain groups, such as older adults with multiple pre-existing conditions or pediatric populations, remains limited in the main body of effectiveness research summarized by regulators.

Key Studies & References Effectiveness and safety of esmolol for ventricular rate control in patients with acute atrial fibrillation or flutter in the emergency department.

Frequently Asked Questions (FAQ)

Common questions about Eimeryl (FAQ)

Q: Why might a healthcare professional prescribe Eimeryl over another medication for the same condition?

A: Official regulatory documents indicate that the medicine’s defining characteristics are its rapid onset of action and its rapid elimination from the body. These unique properties generally inform its use in short-term, acute care settings where a healthcare professional may need to quickly adjust the medication’s effect.

Q: What are the general signs of a possible allergic reaction to Eimeryl?

A: While allergic reactions are uncommon, regulatory documents classify signs of a hypersensitivity reaction as potential adverse events. These signs may include swelling of the lips, tongue, or throat, or the appearance of a rash or hives (urticaria). Any signs of an allergic reaction are a serious event and require immediate medical assessment.

Q: Does Eimeryl have a potential for dependence or withdrawal symptoms?

A: Official documentation for this class of medicine warns against the abrupt discontinuation of the medicine, especially in certain patient populations. Doing so could potentially increase the risk of withdrawal symptoms or cause an acute worsening of the underlying condition. Official guidance indicates that discontinuation is generally done gradually under medical supervision.

Q: Is it safe to consume alcohol while taking Eimeryl?

A: The official labeling advises caution regarding the co-administration of alcohol while the patient is receiving this medicine. Alcohol may potentiate the effects of the medication, which could potentially increase the risk of side effects such as low blood pressure (hypotension).

Q: Does Eimeryl interact with any specific foods, vitamins, or herbal supplements?

A: Yes, official regulatory documents explicitly state that concurrent administration with Thiamine (Vitamin B1) or B-Complex Vitamins may reduce the medicine's effectiveness. This is due to a functional antagonism in how the drug and vitamin are processed.

Q: What types of over-the-counter medicines should be checked for interaction with Eimeryl?

A: The regulatory label warns against using this medication with other products that slow heart rate or lower blood pressure. This general category may include certain over-the-counter cold or flu remedies that contain decongestants or other active ingredients.

Q: Are there any known serious drug-drug interactions associated with Eimeryl?

A: Yes, regulatory documents list serious drug interactions with specific classes of medicines. For instance, combining this drug with non-dihydropyridine calcium channel blockers (such as verapamil or diltiazem) can lead to severe adverse events like profound bradycardia (very slow heart rate) or cardiac failure.

Q: Can Eimeryl be used by people who have existing kidney or liver problems?

A: Official documentation advises caution for patients with severe renal (kidney) impairment due to the potential for a metabolite to accumulate. While caution is generally advised, no routine dose adjustment is specifically required in the labeling for individuals with hepatic (liver) impairment.

Q: How long does it typically take for Eimeryl to start producing noticeable effects?

A: Official documentation describes the medicine as having rapid-onset properties as an acute care medication. The desired physiological effect, such as controlling the heart rate, often occurs within two to ten minutes of the initial loading dose.

Q: What is the general guidance if a person misses a single dose of Eimeryl?

A: Because the medicine is administered as a continuous IV infusion, the concept of a 'missed dose' means an interruption in treatment. Official regulatory guidance covers the necessary steps for restarting the infusion following an interruption, and these procedures are strictly managed by healthcare professionals.

Q: Does Eimeryl affect the ability to drive or operate heavy machinery?

A: Due to common adverse reactions such as dizziness and fatigue, the regulatory label advises caution regarding the ability to drive or operate heavy machinery if these effects are experienced.

Q: What are the common expected signs that indicate Eimeryl is working?

A: The medicine is officially indicated for the management of rapid heart rate and high blood pressure. Therefore, the common clinical signs that indicate the medicine is having an effect are a measured decrease in heart rate or a reduction in elevated blood pressure.

Q: Is Eimeryl a relatively new drug, or has it been on the market for many years?

A: Regulatory records indicate that the active ingredient in Eimeryl (Esmolol) has been available and used in medicine for many years. It received its initial FDA approval in the late 1980s.

Q: Where can I find the official regulatory labeling or package insert for Eimeryl?

A: Official regulatory information, including the full prescribing information and package insert, is made publicly available by government bodies. These documents can be accessed on government-run websites such as the NIH DailyMed or the FDA's drug information databases.

Q: Is Eimeryl considered a 'cure' for the condition it treats?

A: No, official regulatory labeling specifies that the medicine is used for the short-term management or control of acute conditions. It is not classified as a curative treatment.

Q: Is it true that Eimeryl can cause vision changes or blurred vision?

A: Yes, official regulatory documentation lists vision changes, including transient blurred vision, as a documented adverse reaction. However, this is not typically classified as a common occurrence.

Q: What does the term 'contraindication' mean in relation to prescription drugs like Eimeryl?

A: In regulatory documents, a contraindication is a condition, symptom, or circumstance that makes the use of the drug formally inadvisable or strictly prohibited. Use is forbidden because the risk to the patient outweighs any potential benefit.

Q: Is there a risk of overdose associated with Eimeryl?

A: Yes, regulatory documentation contains specific sections dedicated to describing the symptoms and management protocols for accidental or intentional overdose.

Q: Can Eimeryl be taken concurrently with other prescription drugs that treat the same condition?

A: Regulatory guidance advises caution and careful monitoring when this medicine is used with other prescription drugs that treat the same condition (such as other antiarrhythmics or antihypertensives). This is due to the risk of compounding therapeutic and adverse effects.

Q: Is Eimeryl a medication that generally requires routine blood work or other monitoring?

A: Official regulatory labeling mandates that Eimeryl is used only in a closely monitored acute care setting. This use generally involves the continuous monitoring of physiological variables, such as blood pressure and heart rhythm.

Q: Is Eimeryl widely available in generic form?

A: Yes, regulatory records confirm that the active ingredient in Eimeryl is widely available in generic form following the approval of Abbreviated New Drug Applications (ANDAs) by the FDA.

Q: Does Eimeryl have any potential to cause changes in mood or anxiety?

A: The regulatory label documents certain nervous system disorders as possible side effects. These reactions may include confusion, depression, or emotional lability.

Q: What should be avoided while taking Eimeryl to prevent loss of effectiveness? (Partial - Missing foods/supplements)

A: Regulatory documents explicitly state that concurrent administration with Thiamine (Vitamin B1) or B-Complex Vitamins may reduce the medicine's effectiveness. This is due to a functional antagonism against the drug’s mechanism of action.

Q: Does Eimeryl lose its effectiveness over time (e.g., tolerance)? (Partial - Missing cardiac tolerance)

A: Official information for the parasitic use notes the potential for the target organism to develop resistance. For its cardiac use, the regulatory label does not strictly use the word 'tolerance,' but the clinical protocol involves continuous dose titration based on maintaining the desired patient response.

How should Eimeryl be stored and disposed of?

The storage and disposal instructions for Eimeryl (esmolol hydrochloride injection) are governed by official regulatory labeling to ensure product quality and integrity.

Storage Conditions

The injection must be stored at 25 C (77 F), with permitted excursions between 15 C and 30 C. It is mandatory to protect the product from freezing and to avoid excessive heat. The solution must be clear, colorless to light yellow before use.

Handling and Disposal

Eimeryl is supplied in a single-dose container and is strictly for single patient use. It is a regulatory requirement to discard any unused portion of the container after the required dose has been administered. The container must not be used in series connections, and additives should not be introduced.

Disposal of any unused product or waste materials must be carried out in accordance with local institutional and governmental requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eimeryl found in:

A-Z Index: